Publications by authors named "J Bussink"
Cancer-associated fibroblasts (CAFs) represent a group of genotypically non-malignant stromal cells in the tumor micro-environment (TME) of solid tumors that encompasses up to 80% of the tumor volume. Even though the phenotypic diversity and plasticity of CAFs complicates research, it is well-established that CAFs can affect many aspects of tumor progression, including growth, invasion and therapy resistance. Although anti-tumorigenic properties of CAFs have been reported, the majority of research demonstrates a pro-tumorigenic role for CAFs via (in)direct signaling to cancer cells, immunomodulation and extracellular matrix (ECM) remodeling.
View Article and Find Full Text PDFTumor hypoxia contributes to cancer progression and therapy resistance. Several strategies have been investigated to relieve tumor hypoxia, of which some were successful. However, their clinical application remains challenging and therefore they are not used in daily clinical practice.
View Article and Find Full Text PDFArticle Synopsis
- Healthcare systems are significant contributors to CO emissions, making up 7% of emissions in the Netherlands, and evaluating treatments like SBRT and VATS can help reduce their climate impact.
- A life cycle assessment (LCA) was used to compare the carbon emissions of VATS and SBRT for treating Non-Small Cell Lung Cancer, considering patient travel, energy use, and medical supplies.
- Results showed VATS generates about 547 kg CO equivalent while SBRT contributes 172 kg CO equivalent, with energy consumption being the largest factor for both treatments; opportunities exist to reduce emissions by implementing strategies like fast-track recovery and improved treatment efficiencies.
Introduction: Tumor hypoxia is a feature of many solid malignancies and is known to cause radio resistance. In recent years it has become clear that hypoxic tumor regions also foster an immunosuppressive phenotype and are involved in immunotherapy resistance. It has been proposed that reducing the tumors' oxygen consumption will result in an increased oxygen concentration in the tissue and improve radio- and immunotherapy efficacy.
View Article and Find Full Text PDFBackground And Purpose: Radiotherapy (RT) is an integral treatment part for patients with head and neck squamous cell carcinoma (HNSCC), but radioresistance remains a major issue. Here, we use MitoTam, a mitochondrially targeted analogue of tamoxifen, which we aim to stimulate ferroptotic cell death with, and sensitize radioresistant cells to RT.
Materials And Methods: We assessed viability, reactive oxygen species (ROS) production, disruption of mitochondrial membrane potential, and lipid peroxidation in radiosensitive (UT-SCC-40) and radioresistant (UT-SCC-5) HNSCC cells following MitoTam treatment.